Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice
Lena Ostermann, … , Tobias Welte, Ulrich A. Maus
Lena Ostermann, … , Tobias Welte, Ulrich A. Maus
Published February 8, 2021
Citation Information: JCI Insight. 2021;6(3):e140816. https://doi.org/10.1172/jci.insight.140816.
View: Text | PDF
Research Article Pulmonology

Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice

  • Text
  • PDF
Abstract

Alpha-1 antitrypsin (AAT) is a major inhibitor of serine proteases in mammals. Therefore, its deficiency leads to protease–antiprotease imbalance and a risk for developing lung emphysema. Although therapy with human plasma-purified AAT attenuates AAT deficiency–related emphysema, its impact on lung antibacterial immunity is poorly defined. Here, we examined the effect of AAT therapy on lung protective immunity in AAT-deficient (KO) mice challenged with Streptococcus pneumoniae. AAT-KO mice were highly susceptible to S. pneumoniae, as determined by severe lobar pneumonia and early mortality. Mechanistically, we found that neutrophil-derived elastase (NE) degraded the opsonophagocytically important collectins, surfactant protein A (SP-A) and D (SP-D), which was accompanied by significantly impaired lung bacterial clearance in S. pneumoniae–infected AAT-KO mice. Treatment of S. pneumoniae–infected AAT-KO mice with human AAT protected SP-A and SP-D from NE-mediated degradation and corrected the pulmonary pathology observed in these mice. Likewise, treatment with Sivelestat, a specific inhibitor of NE, also protected collectins from degradation and significantly decreased bacterial loads in S. pneumoniae–infected AAT-KO mice. Our findings show that NE is responsible for the degradation of lung SP-A and SP-D in AAT-KO mice affecting lung protective immunity in AAT deficiency.

Authors

Lena Ostermann, Regina Maus, Jennifer Stolper, Lisanne Schütte, Konstantina Katsarou, Srinu Tumpara, Andreas Pich, Christian Mueller, Sabina Janciauskiene, Tobias Welte, Ulrich A. Maus

×

Figure 7

NE degrades collectins SP-A and SP-D in the lungs of AAT-deficient mice.

Options: View larger image (or click on image) Download as PowerPoint
NE degrades collectins SP-A and SP-D in the lungs of AAT-deficient mice....
(A and B) SP-A (A) and SP-D (B) proteins in BAL fluids of untreated or S. pneumoniae–infected WT mice (lanes 3, 4) as compared with AAT-KO mice (lanes 5, 6) as compared with AAT-augmented AAT-KO mice (lanes 7, 8) on day 2 postinfection (F, fragment). (C) Dose-dependent degradation of SP-D by NE in BAL fluids of S. pneumoniae–challenged WT mice (lanes 2–5), while preincubation of NE with AAT fully protected SP-D protein from degradation (lanes 6–9). (D) Incubation of recombinant SP-D protein with NE leads to degradation of recombinant SP-D protein. (E) SP-D protein in BAL fluids of S. pneumoniae–infected NE-KO mice with or without AAT augmentation therapy. (F) Quantification of SP-D protein levels in BAL fluids of mice of the respective treatment groups by ELISA, as indicated. (G–J) Effect of treatment of S. pneumoniae-challenged AAT-KO mice with selective NE inhibitor Sivelestat on SP-D levels in BAL fluids (G and H) and bacterial loads in BAL fluids (I) and lung tissue (J) of AAT-KO mice relative to vehicle treatment, as indicated. (D and E) Lanes 1 to 4 were run on the same gel but were noncontiguous. Data are shown as mean ± SD of n = 6–10 mice per time point and treatment group and are representative of 2 independently performed experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, compared with vehicle-treated mice. (Mann-Whitney U test.)

Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts